Scarica l'app Stockscreener
4.35
6.25%
-0.29
Dopo l'orario di chiusura:
4.41
0.06
+1.38%
Precedente Chiudi:
$4.64
Aprire:
$4.6
Volume 24 ore:
3.61M
Relative Volume:
1.05
Capitalizzazione di mercato:
$585.06M
Reddito:
-
Utile/perdita netta:
$-217.44M
Rapporto P/E:
-2.0046
EPS:
-2.17
Flusso di cassa netto:
$-205.20M
1 W Prestazione:
+11.54%
1M Prestazione:
+76.83%
6M Prestazione:
+38.10%
1 anno Prestazione:
-20.77%
Intervallo 1D:
$4.235
$4.67
Intervallo di 1 settimana:
$3.90
$5.17
Portata 52W:
$1.11
$5.9499
Prime Medicine Inc Stock (PRME) Company Profile
Nome
Prime Medicine Inc
Settore
Industria
Telefono
617-465-0013
Indirizzo
60 FIRST ST., CAMBRIDGE
Confronta PRME con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
4.35 | 609.27M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-27 | Downgrade | Citigroup | Buy → Neutral |
| 2025-05-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-12-10 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-05-20 | Iniziato | H.C. Wainwright | Buy |
| 2024-05-16 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-04-22 | Iniziato | Chardan Capital Markets | Buy |
| 2024-04-08 | Iniziato | TD Cowen | Buy |
| 2024-04-03 | Iniziato | Wedbush | Outperform |
| 2024-01-16 | Downgrade | Stifel | Buy → Hold |
| 2023-12-08 | Iniziato | Citigroup | Neutral |
| 2023-10-09 | Iniziato | BMO Capital Markets | Outperform |
| 2023-07-31 | Iniziato | Guggenheim | Buy |
| 2023-04-18 | Iniziato | Stifel | Buy |
| 2022-11-14 | Iniziato | Goldman | Neutral |
| 2022-11-14 | Iniziato | JP Morgan | Overweight |
| 2022-11-14 | Iniziato | Jefferies | Buy |
| 2022-11-14 | Iniziato | Morgan Stanley | Equal-Weight |
Mostra tutto
Prime Medicine Inc Borsa (PRME) Ultime notizie
Is Prime Medicine Inc. stock a good hedge against inflationFree Risk Assessment Services - jammulinksnews.com
Is Prime Medicine Inc. a good long term investmentMassive profits - Autocar Professional
What analysts say about Prime Medicine Inc. stockAccelerated investment success - Autocar Professional
Prime Medicine Inc. Stock Analysis and ForecastSkyrocketing profit margins - jammulinksnews.com
What drives Prime Medicine Inc. stock priceExponential wealth increase - Autocar Professional
Prime Medicine(PRME) Shares Soar 10.65% on Analyst Rating, Funding Boost - AInvest
Prime Medicine Surges 18% on Funding Catalyst: Is This the Start of a Biotech Breakout? - AInvest
BMO Capital Maintains a Buy on Prime Medicine (PRME), Sets a $10 PT - MSN
Prime Medicine stock price target reiterated at $6 by JMP on CF funding - Investing.com Canada
Prime Medicine (PRME.O) Surges 5.9%: What’s Behind the Intraday Rally? - AInvest
Prime Medicine (PRME): A High-Conviction Biotech Play with a 154% Upside - AInvest
10 Hot Penny Stocks to Invest in Now - Insider Monkey
Cystic Fibrosis Foundation grants new funding to advance development of Prime Medicine’s prime editors - BioWorld MedTech
Prime Medicine, Inc.: Buy Rating Affirmed on Innovative Gene Editing Technology and Strategic Advancements - TipRanks
Prime Medicine stock rating reiterated by H.C. Wainwright on CF partnership - Investing.com Canada
CF Trading Volume Surges 77% to 2.91 Billion, Ranks 364th in Market - AInvest
Prime Medicine Announces CSO Resignation and Transition - The Globe and Mail
Prime Editing's Billion-Dollar Gamble: Can Prime Medicine's $24M Boost Cement Dominance in Cystic Fibrosis? - AInvest
Prime Medicine announces additional funding of up to $24M from CF Foundation - TipRanks
Prime Medicine Announces Additional Funding of Up to $24 - GlobeNewswire
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation - citybiz
Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy - Yahoo Finance
Prime Medicine Announces Additional Funding of Up to $24 Million from the Cystic Fibrosis Foundation to Advance Prime Editing Treatments for Cystic Fibrosis - The Manila Times
Cystic Fibrosis Foundation expands funding for Prime Medicine By Investing.com - Investing.com Nigeria
Prime Medicine Secures Up to $24 Million from Cystic Fibrosis Foundation to Advance Prime Editing Technology for Cystic Fibrosis Treatment - Nasdaq
Cystic Fibrosis Foundation expands funding for Prime Medicine - Investing.com
CF Foundation Backs Prime Medicine with $24M to Develop Cure for 93% of Cystic Fibrosis Patients - Stock Titan
Prime Medicine chief scientific officer to depart, will serve as consultant - Investing.com Nigeria
Prime Medicine, Inc. shares rise 2.99% premarket after Fifty1 AI Labs' successful completion of the REVIVE Clinical Trial. - AInvest
Prime Medicine Inc Azioni (PRME) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):